Just One Wave

Wave Neuroscience (LSI USA ‘25 Innovator) has redefined the conventional boundaries of mental healthcare with its revolutionary SaaS platform, which infuses intelligence into neuromodulation technologies and empowers medical practices to administer precision neuromodulation therapy. This platform is a highly scalable, technology-enabled, first-line therapy that will redefine how we treat challenging conditions like PTSD, depression, traumatic brain injury (TBI), and substance use disorders. Central to their approach is the use of advanced EEG data collection and analytics. This technology doesn't just observe; it actively identifies dysregulated brainwave patterns, guiding personalized neuromodulation to realign brain network behaviors toward peak performance. With data-driven, spatial & frequency-specific stimulation, Wave Neuroscience delivers treatment based on a deeper understanding of brain health, arming both clinicians and patients with the knowledge to navigate the mental healthcare landscape. At the heart of Wave Neuroscience's mission is the integration of objective brain-based biomarkers into mental health care so that there is a better understanding of mental health at the population level with the objective of guiding patients towards optimized treatment paths, minimizing the distress, duration, and severity of mental health conditions. The company has achieved several additional milestones recently, including: ? Two ongoing FDA trials: Standard PTSD protocol + PTSD accelerated protocol ? FDA Breakthrough Device Designation for their MeRT-005 technology for treating PTSD ? In market with 200 contracted subscribers in 16 countries ? Funded bills passed in Ohio, Missouri, Virginia, and Florida creating access to MeRT treatment for Veterans & First Responders ? Is raising its Series C round to accelerate growth following anticipated FDA clearance in Q3 of 2025 and fuel additional clinical trials for MDD, TBI, and SUD. We are thrilled to announce that CEO Fred Walke has been selected to present Wave Neuroscience at LSI USA ‘25 March 17-21, 2025. Join us in Dana Point to meet with Fred and learn more about Wave Neuroscience.

The escalating prevalence of Post-Traumatic Stress Disorder (PTSD) in both military and civilian populations, including first responders, has become a critical public health issue. Currently, there are no FDA approved devices that treat this irreversibly debilitating condition. There is an urgent need for innovative, non-pharmacologic, safe and effective treatments for PTSD to address this underserved patient population. The Breakthrough Device Designation is awarded to treatments that have demonstrated the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. While Breakthrough Designation does not indicate FDA clearance, this designation will help Wave Neuroscience to address this critical healthcare need by accelerating the development, assessment, and ultimately the review of Wave's FDA submissions for the use of the MeRT system for more effective treatment of PTSD patients. #PTSD #MentalHealth #waveneuro #brainhealth

One of the biggest challenges in serving those affected by brain injury is making sure that they are identified in the first place. Not all brain injuries are obvious, not all survivors are aware of their risk, and not all systems that intersect with brain injury have profound awareness of their connection. Give brain injury survivors in your state the best outcomes possible by implementing screening practices that use reliable tools and strategies, and that are customized to your state's programs and services. Learn more about NASHIA's Online Brain Injury Screening and Support System (OBISSS) at: https://lnkd.in/dZ8VuHYw